IMPACT Therapeutics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series D1

  • Investors
  • 18

IMPACT Therapeutics General Information

Description

Developer of novel therapeutics intended to treat cancer and other life-threatening diseases. The company is dedicated towards the discovery and development process of targeted anti-cancer therapeutics based on synthetic lethality.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 12F, New Bund Times Square
  • 399 Haiyang West Road, Pudong District
  • Shanghai, 200126
  • China
+86 021 0000 0000

IMPACT Therapeutics Timeline

2021202220232024
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IMPACT Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series D1) 14-Mar-2022 0000 Completed Generating Revenue
4. Later Stage VC (Series C1) 27-Jul-2020 0000 0000 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 03-Aug-2018 0000 0000 00000 Completed Clinical Trials - General
2. Later Stage VC (Series B) 22-Feb-2016 $10M $16M Completed Clinical Trials - General
1. Later Stage VC (Series A) 14-Jan-2015 $6M $6M Completed Clinical Trials - General
To view IMPACT Therapeutics’s complete valuation and funding history, request access »

IMPACT Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics intended to treat cancer and other life-threatening diseases. The company is dedicated t
Drug Discovery
Shanghai, China
0000
00000000000 0000

000000

sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad m
0000 000000000
Beijing, China
000 As of 0000
00000
0000 0000-00-00
0000000 0000 00000

000000

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
0000 000000000
Hong Kong, Hong Kong
000 As of 0000
00000
0.000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IMPACT Therapeutics Competitors (49)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mabworks Biotech Private Equity-Backed Beijing, China 000 00000 0000000 0000 00000
Harbour BioMed Formerly VC-backed Hong Kong, Hong Kong 000 00000 00000000 00000
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
CureGenetics Venture Capital-Backed Suzhou, China 000.00 00000000000 000.00
Adimab Venture Capital-Backed Lebanon, NH 000 00000 0000000000 0 00000
You’re viewing 5 of 49 competitors. Get the full list »

IMPACT Therapeutics Patents

IMPACT Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200131192-A1 Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6h)-ones and the use thereof Active 10-Jul-2017 000000000
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof Active 27-Feb-2017 0000000000 0
US-20210128535-A1 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof Active 27-Feb-2017 0000000000
US-20190358225-A1 Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof Active 09-Jan-2017 00000000000
JP-2020504139-A Substituted fused heteroaryl compounds as kinase inhibitors and uses thereof Active 09-Jan-2017 A61K31/4985 0
To view IMPACT Therapeutics’s complete patent history, request access »

IMPACT Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Sui Xiong Cai Ph.D Chief Executive Officer
Susie Xu Executive Vice President & Chief Financial Officer
Cong Xu Ph.D Executive Chairman
Chih-Yi Hsieh MD Executive Vice President & Chief Medical Officer
You’re viewing 4 of 6 executive team members. Get the full list »

IMPACT Therapeutics Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BestRide.com Corporation Minority 000 0000 000000 0
CCB Trust Asset Manager Minority 000 0000 000000 0
Dingxin Capital Venture Capital Minority 000 0000 000000 0
Exome Asset Management Asset Manager Minority 000 0000 000000 0
Xiamen C&D Corporation Corporation Minority 000 0000 000000 0
You’re viewing 5 of 18 investors. Get the full list »

IMPACT Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Development of Senaparib (IMP4297) in China (IMPACT Therapeutics / Junshi Biosciences) 20-Aug-2020 00000 0000 Drug Discovery 000 000 0
To view IMPACT Therapeutics’s complete investments history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »